Premium
Resistance to CD95‐mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene
Author(s) -
Müschen Markus,
Re Daniel,
Betz Beate,
Moers Cordula,
Wolf Jürgen,
Niederacher Dieter,
Diehl Volker,
Beckmann Matthias W.
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(200102)9999:9999<::aid-ijc1188>3.0.co;2-5
Subject(s) - fas receptor , loss of heterozygosity , somatic cell , breast cancer , germline mutation , cancer research , mutation , biology , gene , apoptosis , cancer , allele , genetics , programmed cell death
Resistance to CD95 (Apo‐1/Fas)‐mediated apoptosis is a typical feature of breast cancer cells. Recent studies identified deleterious mutations of the CD95 gene not only in a variety of B cell lymphomas but also in a number of solid tumor entities. Therefore, we amplified and sequenced selected regions of the CD95 gene from 48 breast cancer cases and 10 cell lines but no mutation was found. In the presence of both polymorphic alleles, loss of heterozygosity was excluded in 27 informative cases. We conclude, that relevant somatic mutations of the CD95 gene occur, if at all, at a low frequency and are not the primary cause for resistance to CD95‐mediated apoptosis in breast cancer. © 2001 Wiley‐Liss, Inc.